$1.39
2.80%
Nasdaq, Nov 19, 04:00 pm EST. Closed.
ISIN
US88032L2097
Symbol
TENX

Tenax Therapeutics, Inc. Stock price

$1.39
-0.13 8.55% 1M
-10.09 87.89% 6M
-10.80 88.60% YTD
-5.93 81.01% 1Y
-27.52 95.19% 3Y
-2,126.61 99.93% 5Y
-47,998.61 100.00% 10Y
+1.25 892.86% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.04 2.80%
ISIN
US88032L2097
Symbol
TENX
Industry

Is Tenax Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$65.1m
Enterprise Value
$-52.9m
Net debt
positive
Cash
$118.0m
Shares outstanding
32.0m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
1.1 | 0.8
P/B
0.6
Financial Health
Equity Ratio
93.1%
Return on Equity
-54.2%
ROCE
-60.4%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$16.6m | -
SBC as % of FCF
-
SBC Growth 1Y
67.8%
Share Count Growth 1Y
669.9%
Shareholder Yield
-
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-68.6m
Net Income
$-64.9m
Free Cash Flow | ex SBC
$-46.0m | $-62.6m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-95.8%
Net Income
-106.0%
Free Cash Flow
-132.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.3
FCF per Share
$-1.4
Short interest
12.9%
Employees
15
Rev per Employee
$0.0

Tenax Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Tenax Therapeutics, Inc. forecast:

11x Buy
69%
5x Hold
31%

Analyst Opinions

16 Analysts have issued a Tenax Therapeutics, Inc. forecast:

Buy
69%
Hold
31%

Tenax Therapeutics, Inc. Events

Past Events
AUG
10
Special Call - Tenax Therapeutics, Inc.
3 months ago
NOV
13
Special Call - Tenax Therapeutics, Inc.
about one year ago

Financial data from Tenax Therapeutics, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
50% 50%
-
- Research and Development Expense 60 60
209% 209%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -69 -69
96% 96%
-
Net Profit -65 -65
106% 106%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tenax Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tenax Therapeutics, Inc. Stock News

Neutral
PRNewsWire
●
11 days ago
LOS ANGELES, Nov. 9, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misl...
Neutral
PRNewsWire
●
13 days ago
LOS ANGELES, Nov. 6, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misl...
Neutral
GlobeNewsWire
●
15 days ago
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol  Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 ...
More Tenax Therapeutics, Inc. News

Company Profile

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Head office United States
CEO Mr. Giordano
Employees 15
Founded 1967
Website www.tenaxthera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today